Journal of Clinical Pharmacy and Therapeutics · 2020 · 18 citations · 9 references
MedicineImmunologyInfectious DiseasesClinical EpidemiologyImmunopathologyInflammationAcute Lung InjuryAcute Respiratory Distress SyndromeCytokine DysregulationSeptic ShockCohort Study InvestigationCovid-19-associated Acute Respiratory Distress SyndromeCytokine Mediator ReleaseCytokine Release DynamicsPro-inflammatory Cytokine ExpressionRespiratory Failure PrognosisSars-cov-2 InfectionSars-cov-2 Pneumonia
WHAT IS KNOWN AND OBJECTIVE: The coronavirus disease 2019 (COVID-19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL-6 levels or its effects with tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, may alter the course of disease. METHODS: We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID-19. The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS AND DISCUSSION: In this single-centre retrospective cohort study involving 1225 hospitalized patients with SARS-CoV-2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. WHAT IS NEW AND CONCLUSION: Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19.
9
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown et al. · The Lancet · 2020 · 10.2K citations · Full text
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu, Mingfeng Han, Tiantian Li et al. · Proceedings of the National Academy of Sciences · 2020 · 2.8K citations · Full text